Related Experiment Video
Updated: Feb 24, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.1K
Statins in Diabetes Mellitus
Charalambos Vlachopoulos1, Nikolaos Ioakeimidis1, Konstantinos Aznaouridis1
1Hypertension and Cardiometabolic Syndrome Unit, 1st Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens,Greece.
Current Pharmaceutical Design
|August 18, 2017
Summary
Statins effectively lower lipids and protect against cardiovascular disease, even in patients with diabetes. However, these widely used drugs may also increase the risk of developing new-onset diabetes.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Statins are primary lipid-lowering drugs.
- They are proven effective in cardiovascular disease prevention.
- Their benefits extend to patients with diabetes mellitus.
Purpose of the Study:
- To review statin efficacy and safety in diabetic patients.
- To examine the debated diabetogenic effect of statins.
Main Methods:
- Review of current evidence.
- Analysis of randomized clinical trials.
- Broader perspective on drug effects.
Main Results:
- Statins show overall good safety with mild side effects.
- Evidence suggests statins may promote new-onset diabetes mellitus.
- Statins are effective in cardiovascular protection for diabetic individuals.
Conclusions:
- Statins offer significant cardiovascular benefits for patients with diabetes.
- The potential diabetogenic effect of statins warrants consideration.
- Balancing cardiovascular protection and glycemic risk is crucial.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
729
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
729
01:23Dipeptidyl Peptidase 4 Inhibitors
773
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
773
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
650
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
650
01:26Atherosclerosis III: Management
482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.3K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K